The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience

Mohammadreza Bordbar, MD, Ali Sarfaraz, MD, Sezaneh Haghpanah, MD, MPH, Omidreza Zekavat, MD, Soheila Zareifar, MD, and Tahereh Zarei, MS

Abstract
Malignant bone tumors (MBT) account for 3% to 5% of cancers in children younger than 15 years. We aimed to report the outcome of children with MBT in 10 years in Southern Iran. During the study period, 100 patients (57 Osteosarcoma, 43 Ewing sarcoma) with an M/F ratio of 1.56 and a median age of 13.8 years (3.8-17.9) were diagnosed. Metastasis occurred in 27% of patients, mostly in the first 3 months of diagnosis. The mean survival time of MBT altogether was 94.1 months (95% CI: 86.5-101.7). The 5-year overall survival and event-free survivals were 85.2% (95% CI: 74%-91.8%) and 69.2% (95% CI: 56%-79%), respectively. Metastasis was the only independent risk factor of death in our study cohort (Hazard ratio 36.7, 95% CI: 4.8-282.6, P=.001) MBT in children mostly occur in adolescent boys. About one-third of them become metastatic, which is significantly associated with poor outcomes.

Keywords
osteosarcoma, Ewing sarcoma, bone neoplasms, survival

Received July 27, 2021. Accepted for publication August 7, 2021.

Introduction
Cancer is the second most common cause of death worldwide after heart disease. Primary bone tumors are the fourth cause of death among malignant carcinomas after lung, prostate, and breast cancer and the third fetal cancer in pediatrics. Malignant bone tumors (MBT) in children represent 3% to 5% of cancers in children younger than 15 years. The prevalence is almost doubled (7%-8%) in adolescents between the age of 15 to 19 years. The pathogenesis of cancer is multifactorial, with the interaction of environmental risk factors in a genetic predisposition. Primary bone tumors are more prevalent in children and young adolescents than in the adult population. The peak incidence of malignant bone tumors is in adolescents when the pubertal growth spurt is considered a precipitating factor. Previous exposure to radioactive waves increases the risk of malignant bone tumors. Boys are more frequently affected. It is also seen more often in the white race in a subgroup of bone tumors. While primary bone tumors in children are often benign, MBT causes significant mortality and morbidity among children and adolescents. The presenting symptoms of malignant bone tumors are quite variable in children making it difficult to diagnose early. Pain and swelling of the involved bone are the most prevalent initial symptoms. Usually, the pain is nocturnal that is worsened by activity, and is intensified in the later stages of the disease. Other clinical presentations include detecting a palpable mass in bones, limitation of range of motion, limping, vascular and neurological deficits, dyspnea, skin changes, and pathological fractures. Fever, weight loss, and night sweating are systemic symptoms that usually occur in metastatic cases.

The 2 main categories of malignant bone tumors in children are Osteosarcoma and Ewing sarcoma (EWS) or primitive neuroectodermal tumor (PNET), accepted

1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Corresponding Author:
Tahereh Zarei, Hematology Research Center, Shiraz University of Medical Sciences, Zand Avenue, Shiraz 7193711351, Iran.
Email: taherehzarei71@yahoo.com
by the International Classification of Childhood Cancer (ICCC). Other rare subgroups include chondrosarcoma, chordomas, malignant fibrous neoplasms, odontogenic tumors, and unspecified neoplasms. Most of these patients had a subclinical metastatic disease at the time of diagnosis of cancers, even if clinical metastasis is absent.

The data on the epidemiology of pediatric malignant bone tumors in Iran is scarce. A previous study in our center reported the epidemiology of musculoskeletal tumors in children and adults in 1997 to 2008. This study aims to report the clinical characteristics and outcomes of children with malignant primary bone tumors in 10 years since 2008.

**Methods**

This cross-sectional study was performed in Amir Oncology hospital, the primary referral center of children with cancer in Shiraz, Southern Iran, in 2008 to 2018. We reviewed the medical files of 18 years old or younger patients with a confirmed diagnosis of primary malignant bone tumors, including Osteosarcoma, Ewing sarcoma or PNET, chondrosarcoma, and other rare bone tumors according to ICCC. Those with metastatic bone tumors were not included in the study. The demographic data and information about the primary tumor site, initial clinical presentations, presence, and site of metastasis and children’s outcome were recorded from their medical files. Patients were contacted on the phone to follow if they were still alive at the time of the study. In the case of a death event, the time and cause of death were recorded. The Ethics Committee of Shiraz University of Medical Sciences approved the study protocol.

**Statistical Analysis**

We analyzed data with Statistical Package for Social Sciences (SPSS, V22, Chicago, IL, USA). We described quantitative data with median and range, mean and standard deviation (SD), number, and percentages. The Chi-Square test was used to compare qualitative and categorical variables. The independent sample t-test compared the quantitative variables between the 2 groups. The Kaplan-Meier survival analysis was used to estimate the survival times of malignant bone tumors and its subgroups using the Log-rank test to determine the impact of different covariates on bone tumor survival. The Cox regression analysis defined the independent variables affecting survival as the hazard ratio (HR) and 95% confidence interval (CI).

**Results**

During the study period, 100 patients with primary malignant bone tumors were diagnosed in our center, which consisted of 57 patients with Osteosarcoma and 43 patients with EWS. Other rare bone tumors were not reported in our registries during the study period. The general characteristics of the study population are demonstrated in Table 1.

MBT had the highest prevalence in adolescent boys (M/F ratio: 1.56), mostly in ages 10 to 15 years (48%). The male predominance was more prominent in EWS than Osteosarcoma (M/F ratio of 1.69 vs 1.48). The median age of MBT altogether was 13.8 years (3.8-17.9), and 85% of them were older than 10 years. Patients with EWS were relatively younger than patients with Osteosarcoma (Table 1). Girls were generally younger at the time of initial diagnosis than boys in all MBT combined (mean difference 1.4, 95% CI: 0.1-2.7; \( P = .03 \)). The difference was mostly attributed to patients with EWS (mean difference 2.4, 95% CI: 0.3-4.4; \( P = .026 \)).

Long bones of the lower extremity (femur, tibia) were the most frequent primary tumor sites, especially in Osteosarcoma. They were followed by pelvis and shoulder in Ewing sarcoma and pelvis, humerus, and fibula in Osteosarcoma (Figure 1). Most patients declared that pain and swelling were the most common clinical presentations.

Patients with EWS experienced slightly more metastasis events than Osteosarcoma, but the difference was not statistically significant (32.6% vs 22.8%, \( P = .28 \)). Lung was the most common site of metastasis in both groups, especially in Osteosarcoma. Most metastasis events (17 out of 27, 63%) occurred in the first 3 months after diagnosis (78% in EWS and 53% in Osteosarcoma).

We encountered 13 death events in our study population, including 5 deaths (11.6%) in EWS and 8 deaths (14%) in patients with Osteosarcoma (\( P = .72 \)). Patients with EWS died of their illness very sooner than patients with Osteosarcoma. All deaths occurred in the first year of diagnosis in EWS, while 37.5% of deaths in children with Osteosarcoma occurred more than a year since diagnosis.

Figure 2 demonstrates the Kaplan-Meier survival curve of patients with MBT. The mean survival time for bone tumors altogether was 94.1 months (95% CI: 86.5-101.7), which was longer in EWS (96.1 months, 95% CI: 86.2-105.9) compared to Osteosarcoma (91.3 months, 95% CI: 79.9-102.7), but the difference was not significantly different (\( P = .68 \)). The 5-year overall survival (OS) for MBT altogether was 85.2% (95% CI: 74%-91.8%), which was slightly higher in
Ewing sarcoma than Osteosarcoma (88.2% [95% CI: 74%-95%] vs 83.3% [95% CI: 66%-92%]). The mean of event-free survival (EFS) time for MBT altogether was 81 months (95% CI: 72.1-90.0), which was not significantly different between the 2 groups of patients ($P = .58$). The 5-year EFS was 69.2% (95% CI: 56%-79%) in MBT altogether, which was similar in both subgroups (69% [95% CI: 50%-82%] in Osteosarcoma and 68.1% [95% CI: 47%-82%] in EWS).

Table 2 shows the impact of different covariates on the survival of children affected by bone tumors. Among different variables tested, including gender, age, the extent of disease, and tumor location, metastasis was the only variable that significantly lowered the survival rate ($P < .001$) (Figure 3). The Cox regression analysis confirmed that metastatic MBT increased the risk of death by about 40 times (Hazard ratio 39.8 [95% CI: 5.1-308.8], $P < .001$) (Table 3).

**Discussion**

Primary malignant bone tumors are rare in children. Therefore, the data on the clinical course and outcome of this group of tumors is limited. We reported one of the largest studies in our region in a cohort of 100 children with MBT who were followed for a median follow up time of 2.6 years (0.3-9.1). Osteosarcoma was the most common MBT, which was found in 57% of cases. It is similar to many other reports from other centers (range 46.6%-59.5%). The boys were more frequently affected in all MBT, particularly in EWS. The male predominance of MBT, and EWS in particular, was reported in most other reports, while some reported an equal frequency in both genders.

Nearly half of our patients with MBT were adolescents with the age range of 10 to 15 years. It is the time when most children experience their pubertal growth spurt. Cotterill et al previously delineated the association of bone tumors with rapid bone growth. They showed that patients with Osteosarcoma were generally taller than their age-sex-matched healthy controls. Also, patients with EWS younger than 15 years were significantly taller than the general population. Besides, those with Osteosarcoma of lower limbs were taller than those with tumors at other sites. As bones of lower limbs contribute more to the growth spurt than upper limbs, it is
Figure 1. Prevalence of malignant bone tumors by site of presentation.

Figure 2. Kaplan-Meier survival curve of children with primary malignant bone tumors.
not unusual that taller adolescent boys during their pubertal growth spurts are very prone to MBT of lower extremities.

The 5-year OS and EFS in our patients with MBT were 85% and 69%, respectively. The survival probability was similar in patients with Osteosarcoma and EWS. Most previous studies reported a much lower 5-year OS both in children with Osteosarcoma (31.7%-72.6%) and EWS (19%-70%).2,15-23 Approximately 30% of our patients with MBT experienced metastasis. More than 60% of metastases occurred in the first 3 months from diagnosis and were associated with higher mortality. It was the only independent risk factor of mortality in our patients and increased the risk of death by more than 36 times. Many other reports reinforced that disseminated disease significantly reduced the survival rate.24-27 We did not find any association between age, gender, and tumor location and OS in our patients with MBT.

Several factors may affect prognosis in patients with MBT. The results of a large cohort study in the European and American Osteosarcoma Study (EURAMOS-1) on more than 2000 patients with Osteosarcoma revealed

---

### Table 2. Univariate Analysis of the Impact of Different Variables on the Survival of Children With Malignant Bone Tumors.

| Variables            | Malignant bone tumors (n = 100) | Ewing sarcoma (n = 43) | Osteosarcoma (n = 57) |
|----------------------|-------------------------------|-----------------------|----------------------|
| No of events         | No of events                  | No of events          |
| Mean survival (m) (95% CI) | Mean survival (m) (95% CI) | Mean survival (m) (95% CI) |
| Sex                  | P value                       | P value               | P value               |
| Male                 | 8                             | 4                     | 4                     |
| Female               | 5                             | 1                     | 4                     |
| Age group (year)     |                               |                       |                       |
| ≤15                  | 8                             | 3                     | 3                     |
| >15                  | 5                             | 2                     | 3                     |
| Primary site of tumor|                               |                       |                       |
| Extremities          | 11                            | 4                     | 7                     |
| Other sites          | 2                             | 1                     | 1                     |
| Metastasis           |                               |                       |                       |
| Yes                  | 6.19 (43.2-80.7) <.001         | 5                     | 7                     |
| No                   | 107.6 (104.7-110.4) 0          | —                     | 106.6 (101.9-111.3)   |

*In patients with Ewing sarcoma, no statistics were computed because no death event occurred in the non-metastatic group.

---

Figure 3. Kaplan-Meier survival curve of patients with primary malignant bone tumor with and without metastasis.
that metastatic disease, tumor location in the axial skeleton or proximal femur/humerus, male gender, being an adult or adolescent rather than a child, large tumor volume, and chondroblastic histology were associated with a more inferior EFS and OS.\textsuperscript{17} Additionally, pathologic fracture adversely affected 5-year OS in adult patients with Osteosarcoma of extremities in a large cohort of patients registered in the Cooperative Osteosarcoma Study Group (COSS).\textsuperscript{28} The surgical methods (limb salvage surgery vs amputation) seems to produce comparable outcomes regarding local control, but higher 5-year OS in patients undergoing limb salvage surgery.\textsuperscript{29}

A large retrospective cohort study utilizing data from the National Cancer Institute Surveillance Epidemiology and End Results (SEER) to define prognostic groups in patients with Ewing sarcoma of extremities in a large cohort of patients registered in the Cooperative Osteosarcoma Study Group (COSS).\textsuperscript{28} The surgical methods (limb salvage surgery vs amputation) seems to produce comparable outcomes regarding local control, but higher 5-year OS in patients undergoing limb salvage surgery.\textsuperscript{29}

An extensive survey on patients with metastatic MBT at presentation showed that radiotherapy improved OS in patients with Ewing sarcoma but not those with Osteosarcoma.\textsuperscript{31} Similarly, another study emphasized that radiation predicted worse outcome in Osteosarcoma, but was associated with a 24% improved OS and EFS in patients with Ewing sarcoma.\textsuperscript{25} Generally, Osteosarcoma is considered a radioreistant tumor. However, in cases with unresectable tumors, particularly in axial sites or palliative care in symptomatic metastatic lesions, radiation can be used as an adjuvant treatment.\textsuperscript{35}

Given the relatively high rate of metastasis in patients with MBT, which leads to a dismal prognosis despite multimodal treatments, a timely diagnosis may guarantee a better outcome. Pain and swelling are the 2 most common symptoms of MBT, which are easily ignored since they are attributed to physical injuries that frequently happen in the teenage group. Limping is another prominent symptom that should be thoroughly evaluated. Though it is most often due to benign processes such as infections, inflammatory conditions, trauma, and overuse injuries, malignancies should be taken into account, especially when it takes too long to recover or other associated symptoms are present.\textsuperscript{36}

Our study faced some limitations. We did not have access to most patients’ operational data, including tumor volume and post-chemotherapy tumor necrosis. Therefore, their impact on the outcome of patients was not clear. Besides, we did not compare different treatment modalities to know which one has the best results in terms of OS and EFS. Moreover, due to small numbers of death events in our study cohort, the survival analysis results were not robust. Further multicenter studies with larger sample size and longer follow-up are needed to draw firm conclusions.

### Conclusion

MBT occurs mostly in children around puberty. About one-third of them become metastatic even at presentation or during their treatment course. Metastasis adversely affects the outcome and is associated with a dismal prognosis.
Acknowledgments

We would like to thank the Vice-Chancellor of Research and Technology of the Shiraz University of Medical Sciences for its financial support. The study was relevant to the thesis of A. Sarfaraz with project No. 12272.

Author Contributions

M. Bordbar contributed to the study design, conception, and reviewing the manuscript. A. Sarfaraz have done data collection and drafting the manuscript. S. Haghpanah have done data collection and editing the manuscript. T. Zarei have done drafting the paper, performed the research, and edited the final version. All author reads an approved the final version.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Tahereh Zarei https://orcid.org/0000-0002-2689-0254

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi:10.3322/caac.21166
2. Kaatsch P, Strothotte J, Becker C, Bielack SS, Dirksen U, Blettner M. Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival. Acta Oncol. 2016;55(9-10):1145-1151. doi:10.1080/02841032.2016.1195509
3. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information project. Eur J Cancer. 2006;42(13):2124-2135.
4. Ferris I, Tortajada J, Berbel Tornero O, Ortega García JA, et al. Factores de riesgo para los tumores óseos malignos pediátricos [Risk factors for pediatric malignant bone tumors]. An Pediatr (Barc). 2005;63(6):537-547. doi:10.1016/s1695-4033(05)70254-x
5. Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18(6):719-731. doi:10.1016/s1470-2245(17)30186-9
6. Singla A, Geller DS. Musculoskeletal tumors. Pediatr Clin North Am. 2020;67(1):227-245. doi:10.1016/j.pcl.2019.09.014
7. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457-1467. doi:10.1002/cncr.20910
8. Bruland OS, Hoifødt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11(13):4666-4673. doi:10.1158/1078-0432.ccr-05-016
9. Solooki S, Vosoughi AR, Masoomi V. Epidemiology of musculoskeletal tumors in Shiraz, south of Iran. Indian J Med Paediatr Oncol. 2011;32(4):187-191. doi:10.4103/0971-5851.95138
10. Ou JY, Spraker-Perlman H, Dietz AC, Smits-Seemann RR, Kaul S, Kirchhoff AC. Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients. Cancer Epidemiol. 2017;50(Pt A):150-157. doi:10.1016/j.canep.2017.08.015
11. Petca RC, Gavriliiu S, Burnei G. Retrospective clinicopathological study of malignant bone tumors in children and adolescents in Romania – single center experience. J Med Life. 2016;9(2):205-210.
12. Baena-Ocampo LDC, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol. 2009;13(1):16-21. doi:10.1016/j.anndiagpath.2008.07.005
13. Bramer JAM, Somford MP. (i) The epidemiology of primary skeletal malignancy. Orthop Trauma. 2010;24(4):247-251.
14. Cotterill SJ, Wright CM, Pearce MS, Craft AW. Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004;41(9):59-63. doi:10.1002/hjc.10437
15. Laitinen M, Parry M, Albergo JI, Jeyys L, Sumathi V, Grimer R. Outcome of pelvic bone sarcomas in children. J Pediatr Orthop. 2018;38(10):537-542. doi:10.1097/BPO.0000000000000860
16. Majeed SS, Muhammad HA, Ali JS, et al. Treatment outcomes of pediatric patients with ewing sarcoma in a war-torn nation: a single-institute experience from Iraq. J Glob Oncol. 2019;5:JGO.18.00122-JGO.18.00129. doi:10.1200/jgo.18.00122
17. Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36-50. doi:10.1016/j.ejca.2018.11.027
18. Vijayakumar V, Lowery R, Zhang X, et al. Pediatric osteosarcoma: a single institution’s experience. South Med J. 2014;107(11):671-675. doi:10.14423/SMJ.0000000000000187
19. Hsieh MY, Hung GY, Yen HJ, Chen WM, Chen TH. Osteosarcoma in preadolescent patients: experience in a single institute in Taiwan. J Chin Med Assoc. 2009;72(9):455-461. doi:10.1016/s1726-4901(09)70407-1
20. Lee JW, Kim H, Kang HJ, et al. Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation. *Cancer Res Treat.* 2008;40(4):172-177. doi:10.4143/crt.2008.40.4.172

21. Daw NC, Laack NN, McIlvaine EJ, et al. Local control modality and outcome for ewing sarcoma of the femur: a report from the children’s oncology group. *Ann Surg Oncol.* 2016;23(11):3541-3547. doi:10.1245/s10434-016-5269-1

22. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. *J Clin Oncol.* 2015;33(27):3036-3046. doi:10.1200/JCO.2014.59.5256

23. Aung L, Tin AS, Quah TC, Pho RW. Osteogenic sarcoma in children and young adults. *Ann Acad Med Singap.* 2014;43(6):305-313.

24. Krieg AH, Gehmert S, Angst R, Rischewski JR, Kühne T, Hefti F. Léčba Ewingova sarkomu soustředěné do jednoho centra ovlivňuje desetileté dlouhodobé přežití [Impact of single center treatment on ewing sarcoma 10-year long Term survival rates]. *Acta Chir Orthop Traumatol Cech.* 2017;84(6):431-435.

25. Arshi A, Sharim J, Park DY, et al. Prognostic determinants and treatment outcomes analysis of osteosarcoma and ewing sarcoma of the spine. *Spine J.* 2017;17(5):645-655. doi:10.1016/j.spinee.2016.11.002

26. Sofulu Ö Erol B. Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement. *Acta Orthop Traumatol Turc.* 2020;54(3):234-244. doi:10.5152/j.aott.2020.03.79

27. Akhavan A, Binesh F, Shamshiri H, Ghanadi F. Survival of patients with Ewing’s sarcoma in Yazd-Iran. *Asian Pac J Cancer Prev.* 2014;15(12):4861-4864. doi:10.7314/ajpcp.2014.15.12.4861

28. Kelley LM, Schlegel M, Hecker-Nolting S, et al. Pathological fracture and prognosis of high-grade osteosarcoma of the extremities: an analysis of 2,847 consecutive Cooperative Osteosarcoma Study Group (COSS) patients. *J Clin Oncol.* 2020;38(8):823-833. doi:10.1200/jco.19.00827

29. He X, Gao Z, Xu H, Zhang Z, Fu P. A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes. *J Orthop Surg Res.* 2017;12(1):5. doi:10.1186/s13018-016-0500-0

30. Karski EE, McIlvaine E, Segal MR, et al. Identification of discrete prognostic groups in ewing sarcoma. *Pediatr Blood Cancer.* 2016;63(1):47-53. doi:10.1002/pbc.25709

31. Malik AT, Alexander JH, Mayerson JL, Khan SN, Scharschmidt TJ. Is surgical resection of the primary site associated with an improved overall survival for patients with primary malignant bone tumors who have metastatic disease at presentation? *Clin Orthop Relat Res.* 2020;478:2284-2295. doi:10.1097/CORR.0000000000000136

32. Choi Y, Lim DH, Lee SH, et al. Role of radiotherapy in the multimodal treatment of ewing sarcoma family tumors. *Cancer Res Treat.* 2015;47(4):904-912. doi:10.4143/crt.2014.158

33. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. *J Clin Oncol.* 2003;21(8):1574-1580. doi:10.1200/jco.2003.08.165

34. Redondo A, Bagué S, Bernabeu D, et al. Malignant bone tumors (other than ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). *Cancer Chemother Pharmacol.* 2017;80(6):1113-1131. doi:10.1007/s00280-017-3436-0

35. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. *Cancer Treat Rev.* 2009;152:147-164. doi:10.1007/978-1-4419-0284-9_7

36. Herman MJ, Martinek M. The limping child. *Pediatr Rev.* 2015;36(5):184-195; quiz 196. doi:10.1542/pir.36-5-184